Publications by authors named "Sarah Daadi"

Claim this Profile
L
Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation.
Christopher R Weil, Yushen Qian, Rie Von Eyben, Sarah E Daadi, Karen S Corbelli

Leuk Lymphoma· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study.
Ryan C Lynch, Vandana Sundaram, Manisha Desai, Solomon Henry, Douglas Wood, Sarah Daadi

JCO Oncol Pract· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
Margaretha G M Roemer, Ranjana H Advani, Robert A Redd, Geraldine S Pinkus, Yasodha Natkunam, Sarah E Daadi

Cancer Immunol Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Margaretha G M Roemer, Ranjana H Advani, Azra H Ligon, Yasodha Natkunam, Robert A Redd, Sarah E Daadi

J Clin Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
Ranjana H Advani, Sandra J Horning, Richard T Hoppe, Sarah Daadi, John Allen

J Clin Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis